Europe–US new drug manufacturing outsourcing gap widens, reveals GlobalData
From the article
Contract manufacturing facilities located in the US and Europe provide biopharma companies with strategic options to diversify supply chains, access specialized technologies, and speed time-to-market for new drugs. Outsourced dose manufacturing for innovator drugs and biosimilars approved in the US and Europe (the EU and UK) has traditionally oscillated between the two geographies, but there […]
Continue reading on globaldata.comYou might also wanna read
Distributed Biomanufacturing: Rethinking Production and Logistics for Autologous Cell Therapies
bioprocessintl.com·23d ago
Independent US body finds drug shortages are lasting longer as reliability dwindles
bioprocessintl.com·20d ago
Europe's hidden role in global tech: Dutch lithography machines power the semiconductor industry
The article challenges the perception that Europe lags in innovation, highlighting that the world's only manufacturer of complex lithography
csmonitor.com·28d ago
Five EU countries seek unified response to US and pharma pressure on drug pricing
Five EU countries are calling for a united European response to pressure from the U.S. and pharmaceutical companies demanding higher drug pr
politico.eu·27d ago
European biotech leaders explore China's role in global life sciences innovation at Paris roundtable
A roundtable discussion in Paris examined China's evolving role in the global biotechnology ecosystem, focusing on how European life science
jdsupra.com·15d ago
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
bioprocessintl.com·22d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.